Our second finding primarily focuses on the impact of immunologic markers in the tumour microenvironment, specifically how a low percentage of CD8+ lymphocytes, high percentage of Galectin-9+ NPC cells and high percentage of Foxp3+ lymphocytes affect the outcome of recurrent NPC. This evidence concerns the gene LGALS9 and neoplasm.